| CTSH |
Report |
Q2 revenue |
IN-LINE |
pred ~$5.50B vs. cons $5.49B |
MEDIUM |
| CTSH |
Report |
Q2 adjusted EPS |
BEAT |
pred ~$1.41 vs. cons $1.38 |
MEDIUM |
| CTSH |
Report |
Q2 adjusted operating margin |
IN-LINE |
pred ~15.9% vs. cons 15.8% |
LOW |
| CTSH |
Guide |
Q3 revenue |
LOWER |
guide ~$5.62B vs. cons $5.66B (2026Q3) |
MEDIUM |
| CTSH |
Guide |
Constant-currency revenue growth |
UNCHANGED |
guide ~5.25% midpoint vs. cons 5.25% (FY2026) |
MEDIUM |
| CTSH |
Guide |
Adjusted operating margin |
UNCHANGED |
guide ~16.1% midpoint vs. cons 16.1% (FY2026) |
MEDIUM |
| CTSH |
Guide |
Adjusted EPS |
BETTER |
guide ~$5.72 midpoint vs. cons $5.70 (FY2026) |
LOW |
| CTSH |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.5% |
— |
MEDIUM |
| CTSH |
Return |
5-day cumulative residual |
-4.5% (FOLLOW-THROUGH) |
Q3 revenue guide of ~$5.62B vs. consensus $5.66B leaves an elevated Q4 requirement and should pull out-period estimates lower despite a Q2 EPS beat. |
MEDIUM |